Well at least we can get back to worrying about the usual stuff again, now.
Must've been a bit contentious getting to agreement for this 2 year extension at credit card rates, and deleting conversion from Hepa's options. Wonder if conflict of interest was the issue with the Hepa BoD seat, and whether this will bring a Hepa represenative back to the BoD now?
Go Zenith